Altamira Therapeutics - Aset Bersih saben Siji Saham CYTO

Altamira Therapeutics (CYTO) maintains an impeccable image in biotechnology due to high confidence in the quality of its developments. Altamira Therapeutics (CYTO) relies on the OligoPhore system, monetizing royalties and the sale of nasal assets. However, geopolitical risks and logistics disruptions complicate international trials. The book value per ordinary share on the GURU.Markets chart reflects the impact of these factors, with the indicator holding around 0.00.

Altamira Therapeutics' development of innovative RNA drug delivery systems requires significant capital expenditures in intangible assets. This metric reflects the residual value of net assets per common share after deducting all liabilities, allowing for an assessment of the business's intrinsic value via the book value per common share indicator on the GURU.Markets platform to determine the capital's defensive potential.